| Identification | Back Directory | [Name]
C18 3'-sulfo Galactosylceramide (d18:1/18:0) | [CAS]
244215-65-4 | [Synonyms]
N-Octadecanoyl-sulfatide
-sulfo Galactosylceramide (d18:1/18:0)
C18 3'-sulfo Galactosylceramide (d18:1/18:0)
Octadecanamide, N-[(1S,2R,3E)-2-hydroxy-1-[[(3-O-sulfo-β-D-galactopyranosyl)oxy]methyl]-3-heptadecen-1-yl]- | [Molecular Formula]
C42H81NO11S | [MDL Number]
MFCD22419166 | [MOL File]
244215-65-4.mol | [Molecular Weight]
808.16 |
| Hazard Information | Back Directory | [Description]
C18 3'-sulfo Galactosylceramide is a member of the sulfatide class of glycolipids. It is a minor endogenous sphingolipid produced from C18 ceramide and UDP-galactose in the endoplasmic reticulum followed by sulfation in the Golgi apparatus.1 C18 3'-sulfo Galactosylceramide levels are increased in brain tissue isolated from mice with an arylsulfatase A deficiency (ASA-KO), particularly in lipid raft fractions.2,3 Plasma levels of C18 3’-sulfo galactosylceramide positively correlate with disability progression in patients with relapsing-remitting multiple sclerosis using the Expanded Disability Status Scale.4 It is also increased in plasma from patients with metachromatic leukodystrophy (MLD).5 Brain levels of short-chain sulfatides, including C18 3’-sulfo galactosylceramide, decrease with age in mice and humans.2,6 As this product is derived from a natural source, there may be variations in the sphingoid backbone. | [Uses]
N-Octadecanoyl-sulfatide is an ester product. | [Definition]
ChEBI: 3-O-Sulfogalactosylceramide (d18:1/18:0) is a glycosphingolipid. | [References]
1. Takahashi, T., and Suzuki, T. Role of sulfatide in normal and pathological cells and tissues J. Lipid Res. 53(8),1437-1450(2012).
2. Isaac, G., Pernber, Z., Gieselmann, V., et al. Sulfatide with short fatty acid dominates in astrocytes and neurons FEBS J. 273(8),1782-1790(2006).
3. Moyano, A.L., Li, G., Lopez-Rosas, A., et al. Distribution of C16:0, C18:0, C24:1, and C24:0 sulfatides in central nervous system lipid rafts by quantitative ultra-high-pressure liquid chromatography tandem mass spectrometry Anal. Biochem. 467,31-39(2014).
4. Moyano, A.L., Pituch, K., Li, G., et al. Levels of plasma sulfatides C18 : 0 and C24 : 1 correlate with disease status in relapsing-remitting multiple sclerosis J. Neurochem. 127(5),600-604(2013).
5. Saville, J.T., Smith, N.J.C., Fletcher, J.M., et al. Quantification of plasma sulfatides by mass spectrometry: Utility for metachromatic leukodystrophy Anal. Chim. Acta 955,79-85(2017).
6. Svennerholm, L., and St?llberg-Stenhagen, S. Changes in the fatty acid composition of cerebrosides and sulfatides of human nervous tissue with age J. Lipid Res. 9(2),215-225(1968). |
|
| Company Name: |
Alfa Chemistry
|
| Tel: |
1-516-6625404 13060007561 |
| Website: |
https://www.alfa-chemistry.com |
| Company Name: |
Enzo Biochem Inc
|
| Tel: |
Enzo Biochem Inc. 13797054060 |
| Website: |
www.enzo.com |
|